|
35. |
HIV and SIV Diversity
|
| 36. |
Vpr
|
| 37. |
Molecular Virology
|
| 38. |
Viral and Cellular Proteins on the Virion Surface
|
| 39. |
Envelope-Receptor Interactions
|
| 40. |
Chemokines and Chemokine Receptors
|
| 41. |
CD4 T-Helper Responses to HIV
|
| 42. |
CD8+ T-Cell Responses and Influences of CD4+ T Cells
|
| 43. |
Neutralizing Antibodies
|
| 44. |
DC-SIGN and Dendritic Cells
|
| 45. |
Exposed Uninfected Individuals
|
| 46. |
Immunology: Miscellaneous
|
| 47. |
DNA Vaccines
|
| 48. |
Protein and Inactivated Virus Vaccines
|
| 49. |
Vaccine-Related Studies
|
| 50. |
Therapeutic Vaccine Studies
|
| 51. |
Impact of Host Genetics on Viral Transmission and Disease Progression
|
| 52. |
Pathogenesis Studies in Animal Models
|
| 53. |
Pathogenesis: Miscellaneous
|
| 54. |
Pathogenesis of Acute HIV Infection
|
| 55. |
Diagnosis and Treatment of Primary Infection
|
| 56. |
Acute Infection: Resistance, Fitness, and Transmission
|
| 57. |
Novel Antiretroviral Chemotherapeutic Agents
|
| 58. |
Entry Inhibitors
|
| 59. |
Targeting the Viral Reservoir
|
| 60. |
Antiretroviral Chemotherapy in Drug Naïve Patients
|
| 61. |
Antiretroviral Chemotherapy in Previously Treated Individuals
|
| 62. |
Pharmacokinetics of Antiretroviral Drugs
|
| 63. |
Drug-Drug Interactions
|
| 64. |
Therapeutic Drug Monitoring
|
| 65. |
Antiretroviral Chemotherapy in Resource Limited Settings
|
| 66. |
Antiretroviral Chemotherapy: Predictors of Sucessful Outcome
|
| 67. |
Disease Progression/Effects of Treatment
|
| 68. |
Immune Reconstitution with Antiretroviral Chemotherapy
|
| 69. |
Immunopathogenesis Issues Addressed by Therapeutic Interventions
|
| 70. |
Thymic Function and Immune Reconstitution
|
| 71. |
IL-2 and Other Forms of Immunotherapy
|
| 72. |
Treatment Interruption
|
| 73. |
Adherence to Therapy
|
| 74. |
Antiretroviral Chemotherapy: Miscellaneous Topics
|
| 75. |
Resistance to Antiretroviral Chemotherapeutic Agents
|
| 76. |
HIV Resistance and Fitness
|
| 77. |
Resistance Testing in Drug Selection
|
| 78. |
Diagnostic Techniques: Viral Sequencing Technologies
|
| 79. |
Diagnostic Techniques: Assays for Serologic Diagnosis and Viral Quantitation
|
| 80. |
Viral, Fungal, and Protozoal Opportunistic Infections
|
| 81. |
HHV-8, Kaposi's Sarcoma, and HIV-Related Lymphoma
|
| 82. |
Tuberculosis and Other Mycobacterial Infections
|
| 83. |
Discontinuation of Prophylaxis/Risk of Opportunistic Infections
|
| 84. |
HCV Co-Infection and HIV/HCV Immune Responses
|
| 85. |
HCV Co-Infection: Diagnosis and Pathogenesis
|
| 86. |
HCV Co-Infection: Treatment
|
| 87. |
Hepatitis Virueses: Influence on Morbidity, Mortality, and Response to Antiretroviral Therapy
|
| 88. |
GBV-C Co-Infection
|
| 89. |
HBV Co-Infection
|
| 90. |
Incidence, Prevalence, and Pathogenic Correlates of Insulin Resistance and Lipodystrophy Syndrome
|
| 91. |
Cardiovascular Disease Risk
|
| 92. |
Switch Studies/Treatment of Lipodystrophy Syndromes
|
| 93. |
Mitochondrial Toxicity/Hyperlactatemia
|
| 94. |
Osteopenia/Osteoporosis
|
| 95. |
Organ Specific Toxicities/Complications
|
| 96. |
HIV-Associated Encephalopathy
|
| 97. |
Neuropathogenesis
|
| 98. |
Neuropathogenesis: Effects of Therapy
|
| 99. |
Predictors and Causes of Mortality in HIV Disease
|
| 100.
|
Molecular Epidemiology |
| 101.
|
HIV Incidence and Transmission
|
| 102.
|
Effect of Gender/Sex on Viral Load, Pharmacokinetics and Responses to Antiretroviral Therapy
|
| 103.
|
Cervico-Vaginal HIV Shedding: Immunologic and Virologic Correlates and Microbicides
|
| 104.
|
Perinatal Transmission
|
| 105.
|
Pediatric HIV Infection: Disease Progression and Responses to Therapy
|
| 106.
|
Pediatric Opportunistic Infections
|
to view
a poster.